Top ▲
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
ubiquitin specific peptidase 1
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
ubiquitin specific peptidase 2
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
ubiquitin specific peptidase 5
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
ubiquitin specific peptidase 7 Show summary »« Hide summary
|
|||||||||||||||||||||||||||
|
ubiquitin specific peptidase 8 Show summary »« Hide summary
|
|||||||||||||||||||||||||||
|
ubiquitin specific peptidase 14
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
ubiquitin specific peptidase 21 Show summary »« Hide summary
|
|||||||||||||||||||||||||||
|
ubiquitin specific peptidase 28 Show summary »« Hide summary
|
|||||||||||||||||||||||||||
|
ubiquitin specific peptidase 30 Show summary »« Hide summary
|
* Key recommended reading is highlighted with an asterisk
* El-Hamaky AA, El-Hamamsy MH, El-Moselhy TF, Sharafeldin N, Tawfik HO. (2025) Therapeutic targeting of ubiquitin-specific protease 7 (USP7): Mechanistic insights, dysregulation, and advances in drug discovery. Eur J Med Chem, 296: 117872. [PMID:40544656]
* Maubach G, Hamann L, Stein M, Haak E, Naumann M. (2026) Deubiquitinase inhibitors: from evolving concepts to preclinical evaluation. Drug Discov Today,: 104751 [Epub ahead of print]. [PMID:42526627]
* Torrado C, Ashton NW, D'Andrea AD, Yap TA. (2025) USP1 inhibition: A journey from target discovery to clinical translation. Pharmacol Ther, 271: 108865. [PMID:40274197]
1. An T, Lu Y, Yan X, Hou J. (2022) Insights Into the Properties, Biological Functions, and Regulation of USP21. Front Pharmacol, 13: 944089. [PMID:35846989]
2. Bratt AS, Kilgas S, Guzman MIT, Magin RS, Maisonet IJ, Starnbach CA, Teh WP, Varca AC, Hu B, Guzman ET. (2025) Pharmacologic interrogation of USP28 cellular function in p53 signaling. Cell Chem Biol, Epub ahead of print. DOI: 10.1016/j.chembiol.2025.08.002
3. Chrzanowski J, Nowicka J, Koralewski R, Joachimiak L, Gzik A, Borek B, Brzezinska J, Kusmirek D, Olejniczak S, Matyszewski K et al.. (2026) Structure-Guided Discovery of OAT-4828 as Potent, Selective, and Orally Bioavailable USP7 Inhibitor with In Vivo Antileukemic Activity. J Med Chem, 69 (10): 12502-12518. [PMID:42090583]
4. Dang F, Bai L, Dong J, Hu X, Wang J, Paulo JA, Xiong Y, Liang X, Sun Y, Chen Y et al.. (2023) USP2 inhibition prevents infection with ACE2-dependent coronaviruses in vitro and is protective against SARS-CoV-2 in mice. Sci Transl Med, 15 (725): eadh7668. [PMID:38055802]
5. Davis MI, Pragani R, Fox JT, Shen M, Parmar K, Gaudiano EF, Liu L, Tanega C, McGee L, Hall MD et al.. (2016) Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models. J Biol Chem, 291 (47): 24628-24640. [PMID:27681596]
6. Dexheimer TS, Rosenthal AS, Luci DK, Liang Q, Villamil MA, Chen J, Sun H, Kerns EH, Simeonov A, Jadhav A et al.. (2014) Synthesis and Structure-Activity Relationship Studies of N-Benzyl-2-phenylpyrimidin-4-amine Derivatives as Potent USP1/UAF1 Deubiquitinase Inhibitors with Anticancer Activity against Nonsmall Cell Lung Cancer. J Med Chem, 57 (19): 8099-110. [PMID:25229643]
7. Göricke F, Vu V, Smith L, Scheib U, Böhm R, Akkilic N, Wohlfahrt G, Weiske J, Bömer U, Brzezinka K et al.. (2023) Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21. J Med Chem, 66 (5): 3431-3447. [PMID:36802665]
8. Gavory G, O'Dowd CR, Helm MD, Flasz J, Arkoudis E, Dossang A, Hughes C, Cassidy E, McClelland K, Odrzywol E et al.. (2018) Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. Nat Chem Biol, 14 (2): 118-125. [PMID:29200206]
9. Kazi NH, Klink N, Gallant K, Kipka GM, Gersch M. (2025) Chimeric deubiquitinase engineering reveals structural basis for specific inhibition of the mitophagy regulator USP30. Nat Struct Mol Biol, 32 (9): 1776-1786. [PMID:40325251]
10. Kluge AF, Lagu BR, Maiti P, Jaleel M, Webb M, Malhotra J, Mallat A, Srinivas PA, Thompson JE. (2018) Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Bioorg Med Chem Lett, 28 (15): 2655-2659. [PMID:29935771]
11. Lamberto I, Liu X, Seo HS, Schauer NJ, Iacob RE, Hu W, Das D, Mikhailova T, Weisberg EL, Engen JR et al.. (2017) Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. Cell Chem Biol, 24 (12): 1490-1500.e11. [PMID:29056421]
12. Lee BH, Lee MJ, Park S, Oh DC, Elsasser S, Chen PC, Gartner C, Dimova N, Hanna J, Gygi SP et al.. (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature, 467 (7312): 179-84. [PMID:20829789]
13. Lee TG, Woo SM, Seo SU, Kim S, Park JW, Chang YC, Kwon TK. (2023) Inhibition of USP2 Enhances TRAIL-Mediated Cancer Cell Death through Downregulation of Survivin. Int J Mol Sci, 24 (16). [PMID:37628997]
14. Leger PR, Hu DX, Biannic B, Bui M, Han X, Karbarz E, Maung J, Okano A, Osipov M, Shibuya GM et al.. (2020) Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity. J Med Chem, 63 (10): 5398-5420. [PMID:32302140]
15. Liao Y, Zhang W, Liu Y, Zhu C, Zou Z. (2024) The role of ubiquitination in health and disease. MedComm (2020), 5 (10): e736. [PMID:39329019]
16. Maubach G, Hamann L, Stein M, Haak E, Naumann M. (2026) Deubiquitinase inhibitors: from evolving concepts to preclinical evaluation. Drug Discov Today,: 104751 [Epub ahead of print]. [PMID:42526627]
17. O'Brien DP, Jones HBL, Shi Y, Guenther F, Vendrell I, Viner R, Brennan PE, Mead E, Zarganes-Tzitzikas T, Davis JB et al.. (2025) Structural Dynamics of the Ubiquitin Specific Protease USP30 in Complex with a Cyanopyrrolidine-Containing Covalent Inhibitor. J Proteome Res, 24 (2): 479-490. [PMID:39804742]
18. Peng J, Jiang K, Bu J, Wang F. (2020) Ubiquitin-specific protease inhibitors, and preparation method therefor and application thereof. Patent number: WO2020224652A1. Assignee: Chaser Therapeutics Inc. Priority date: 08/05/2020. Publication date: 12/11/2020.
19. Rusilowicz-Jones EV, Jardine J, Kallinos A, Pinto-Fernandez A, Guenther F, Giurrandino M, Barone FG, McCarron K, Burke CJ, Murad A et al.. (2020) USP30 sets a trigger threshold for PINK1-PARKIN amplification of mitochondrial ubiquitylation. Life Sci Alliance, 3 (8). [PMID:32636217]
20. Tan L, Shan H, Han C, Zhang Z, Shen J, Zhang X, Xiang H, Lu K, Qi C, Li Y et al.. (2022) Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer. J Med Chem, 65 (20): 13645-13659. [PMID:36221183]
21. Wang X, Liu Z, Zhang L, Yang Z, Chen X, Luo J, Zhou Z, Mei X, Yu X, Shao Z et al.. (2018) Targeting deubiquitinase USP28 for cancer therapy. Cell Death Dis, 9 (2): 186. [PMID:29415985]
22. Wang X, Mazurkiewicz M, Hillert EK, Olofsson MH, Pierrou S, Hillertz P, Gullbo J, Selvaraju K, Paulus A, Akhtar S et al.. (2016) The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci Rep, 6: 26979. [PMID:27264969]
23. Wang Y, Jiang Y, Ding S, Li J, Song N, Ren Y, Hong D, Wu C, Li B, Wang F et al.. (2018) Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade. Cell Res, 28 (12): 1186-1194. [PMID:30254335]
24. Zhang J, Liu B, Ren R, Song S, Bao X, Huan X, Li H, Xu J, Yu T, Wang R et al.. (2025) Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 Inhibitors. J Med Chem, 68 (3): 3673-3699. [PMID:39902599]
25. Zhang S, Guo Y, Zhang S, Wang Z, Zhang Y, Zuo S. (2023) Targeting the deubiquitinase USP2 for malignant tumor therapy (Review). Oncol Rep, 50 (4). [PMID:37594087]
26. Zhou D, Xu Z, Huang Y, Wang H, Zhu X, Zhang W, Song W, Gao T, Liu T, Wang M et al.. (2023) Structure-based discovery of potent USP28 inhibitors derived from Vismodegib. Eur J Med Chem, 254: 115369. [PMID:37075624]
Database page citation:
C19: Ubiquitin-specific protease. Accessed on 17/11/2026. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=730.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Fabbro D, Gibb AJ, Kelly E, Mathie AA, Peach CJ, Veale EL, Armstrong JF, Faccenda E, Harding SD, Southan C, Davies JA et al. (2025) The Concise Guide to PHARMACOLOGY 2025/26: Enzymes. Br J Pharmacol. 182: S307-S403.


DUBs operate in oposition to ubiquitination mediated by E1, E2, and E3 enzymes. They are involved in a variety of pathological conditions and are being explored as druggable targets for which pharmacological inhibition offer therapeutic potenial [15-16].